Stock Track | Zymeworks Soars 5.45% Intraday on Positive Analyst Ratings and Price Target Increases

Stock Track03-04

Zymeworks Inc (ZYME) saw its stock price surge 5.45% during Tuesday's intraday trading session, driven by a wave of positive analyst sentiment.

Multiple financial institutions issued favorable ratings on the healthcare stock, with Leerink Partners maintaining an Outperform rating, Truist Financial reiterating a Buy rating with a $40 price target, and Stifel Nicolaus reaffirming a Buy rating. Notably, Stifel raised its price target for Zymeworks from $40 to $47, indicating increased confidence in the company's future performance.

The collective bullish outlook from analysts appears to have boosted investor confidence, leading to significant buying pressure and the stock's substantial intraday gain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154856625?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 03:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154856625","market":"hk","top_or_hot":-1,"title":"Stock Track | Zymeworks Soars 5.45% Intraday on Positive Analyst Ratings and Price Target Increases","media":"Stock Track","content":"<p>Zymeworks Inc (ZYME) saw its stock price surge 5.45% during Tuesday's intraday trading session, driven by a wave of positive analyst sentiment.</p><p>Multiple financial institutions issued favorable ratings on the healthcare stock, with Leerink Partners maintaining an Outperform rating, Truist Financial reiterating a Buy rating with a $40 price target, and Stifel Nicolaus reaffirming a Buy rating. Notably, Stifel raised its price target for Zymeworks from $40 to $47, indicating increased confidence in the company's future performance.</p><p>The collective bullish outlook from analysts appears to have boosted investor confidence, leading to significant buying pressure and the stock's substantial intraday gain.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zymeworks Soars 5.45% Intraday on Positive Analyst Ratings and Price Target Increases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zymeworks Soars 5.45% Intraday on Positive Analyst Ratings and Price Target Increases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-04 03:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zymeworks Inc (ZYME) saw its stock price surge 5.45% during Tuesday's intraday trading session, driven by a wave of positive analyst sentiment.</p><p>Multiple financial institutions issued favorable ratings on the healthcare stock, with Leerink Partners maintaining an Outperform rating, Truist Financial reiterating a Buy rating with a $40 price target, and Stifel Nicolaus reaffirming a Buy rating. Notably, Stifel raised its price target for Zymeworks from $40 to $47, indicating increased confidence in the company's future performance.</p><p>The collective bullish outlook from analysts appears to have boosted investor confidence, leading to significant buying pressure and the stock's substantial intraday gain.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZYME","symbol_name":"ZYMEWORKS INC (US)","start_time":0,"source_url":"","article_id":"1154856625","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154856625","pubTimestamp":1772565882,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zymeworks Inc (ZYME) saw its stock price surge 5.45% during Tuesday's intraday trading session, driven by a wave of positive analyst sentiment.Multiple financial institutions issued favorable ratings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZYME":"ZYMEWORKS INC (US)"},"translate_title":"个股追踪|Zymeworks盘中大涨5.45%，因分析师正面评级和目标价上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":1},"content_text":"Zymeworks Inc (ZYME) saw its stock price surge 5.45% during Tuesday's intraday trading session, driven by a wave of positive analyst sentiment.Multiple financial institutions issued favorable ratings on the healthcare stock, with Leerink Partners maintaining an Outperform rating, Truist Financial reiterating a Buy rating with a $40 price target, and Stifel Nicolaus reaffirming a Buy rating. Notably, Stifel raised its price target for Zymeworks from $40 to $47, indicating increased confidence in the company's future performance.The collective bullish outlook from analysts appears to have boosted investor confidence, leading to significant buying pressure and the stock's substantial intraday gain.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154856625","isCrawlerRequest":true}